Maureen Lannan, MD
Family Medicine · Sulphur, LANPI 1023014313
Payments from drug & device makers
Across 368 payments — averaging $15.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$1K
- Lilly USA, LLC$534
- Amgen$429
- AbbVie$426
- Sanofi-aventis U.S. LLC$243
- plus $2K from 26 others
What the payments were for
- Food & beverage$5,56999%
- Education$421%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 87 | $1,116 |
| AstraZeneca | 64 | $1,056 |
| Lilly USA, LLC | 35 | $534 |
| Amgen | 29 | $429 |
| AbbVie(2 entities) | 28 | $426 |
| Sanofi-aventis U.S. LLC | 18 | $243 |
| Merck | 11 | $161 |
| Astellas Pharma US Inc | 9 | $155 |
| GSK | 7 | $150 |
| Boehringer Ingelheim | 10 | $149 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $143 |
| Abbott | 7 | $120 |
| Pfizer | 7 | $107 |
| Esperion Therapeutics, Inc. | 6 | $99 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $81 |
| Novartis | 5 | $78 |
| Supernus Pharmaceuticals, Inc. | 5 | $77 |
| Axsome Therapeutics, Inc. | 3 | $73 |
| Exact Sciences | 3 | $62 |
| Idorsia Pharmaceuticals US Inc | 3 | $44 |
| Johnson & Johnson | 3 | $44 |
| Bayer | 2 | $37 |
| Biohaven Pharmaceuticals, Inc. | 2 | $35 |
| Shire North American Group Inc | 3 | $34 |
| Jazz Pharmaceuticals Inc. | 2 | $31 |
| Eisai Inc. | 2 | $28 |
| Amarin Pharma, Inc. | 1 | $24 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Ironshore Pharmaceuticals Inc. | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Aytu Biopharma, Inc. | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $11 |
How this compares
$5,611 in reported general payments places this provider in the 80th percentile of 1,469 family medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 123 | $152,198 |
| OzempicSemaglutide | 116 | $149,122 |
| EliquisApixaban | 80 | $81,900 |
| TrulicityDulaglutide | 17 | $30,081 |
| XareltoRivaroxaban | 32 | $28,721 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $22,683 |
| TrintellixVortioxetine Hydrobromide | 23 | $19,469 |
| FarxigaDapagliflozin Propanediol | 17 | $15,510 |
| JardianceEmpagliflozin | 15 | $15,148 |
| MyrbetriqMirabegron | 26 | $12,278 |
| EntrestoSacubitril/Valsartan | 17 | $11,400 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 16 | $8,922 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $7,704 |
| JanuviaSitagliptin Phosphate | 12 | $6,462 |
| Levothyroxine Sodium | 532 | $4,656 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $534 | $182,279140 claims |
| Novo NordiskOzempic | $1,116 | $149,122116 claims |
| PfizerEliquis, Dilantin | $107 | $84,15592 claims |
| Johnson & JohnsonXarelto | $44 | $28,72132 claims |
| AstraZenecaFarxiga, Symbicort | $1,056 | $23,21434 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $143 | $19,46923 claims |
| Boehringer IngelheimJardiance | $149 | $15,14815 claims |
| Astellas Pharma US IncMyrbetriq | $155 | $12,27826 claims |
| NovartisEntresto | $78 | $11,40017 claims |
| MerckJanuvia | $161 | $6,46212 claims |
| AbbVieLumigan, Synthroid | $426 | $5,26980 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Sulphur
- Phillip ConnerSulphur$71K
- Clinton GuilloryMonroe$18.5M
- Jason MorrisLake Charles$18M
- Michael SeepLake Charles$9.1M
- William NaboursLake Charles$3M
- Ramon VargasKenner$2.1M
- Stephen JonesNew Orleans$513K
- Joshua WhatleyLake Charles$366K
- Richard JeansonneMandeville$362K
- Kristen ThomasNew Orleans$361K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.